Neuroinflammation in PD

Neuroinflammation in PD

published: true
tags: kind:mechanism, section:mechanisms, state:published, evidence:strong
editor: markdown
pageId: 15242
dateCreated: "2026-03-19T13:44:19.122Z"
dateUpdated: "2026-04-01T14:00:00.000Z"
lastReviewed: "2026-04-01T14:00:00.000Z"
refs:
heneka2018:
authors: Heneka MT, et al.
title: Neuroinflammation in Parkinson's disease
journal: Lancet Neurology
year: 2018
doi: 10.1016/S2213-2600(18)30069-2
pmid: 29371075
streit2012:
authors: Streit WJ, et al.
title: 'Microglial pathology: I.

Neuroinflammation in PD

published: true
tags: kind:mechanism, section:mechanisms, state:published, evidence:strong
editor: markdown
pageId: 15242
dateCreated: "2026-03-19T13:44:19.122Z"
dateUpdated: "2026-04-01T14:00:00.000Z"
lastReviewed: "2026-04-01T14:00:00.000Z"
refs:
heneka2018:
authors: Heneka MT, et al.
title: Neuroinflammation in Parkinson's disease
journal: Lancet Neurology
year: 2018
doi: 10.1016/S2213-2600(18)30069-2
pmid: 29371075
streit2012:
authors: Streit WJ, et al.
title: 'Microglial pathology: I. When microglia go bad'
journal: Progress in Neurobiology
year: 2012
doi: 10.1016/j.pneurobio.2012.05.001
kim2015:
authors: Kim C, et al.
title: Antagonizing neural toll-like receptor 2 prevents synucleinopathy by activating autophagy PMID: 41831074
journal: Cell Reports
year: 2015
doi: 10.1016/j.celrep.2015.03.017
george2013:
authors: George S, et al.
title: 'α-Synuclein: The long distance runner'
journal: Annals of Neurology
year: 2013
doi: 10.1002/ana.24723
gordon2018:
authors: Gordon R, et al.
title: Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice PMID: 41798290
journal: Nature Medicine
year: 2018
doi: 10.1038/s41591-018-0053-5
liddelow2017:
authors: Liddelow SA, et al.
title: Neurotoxic reactive astrocytes are induced by activated microglia
journal: Nature
year: 2017
doi: 10.1038/nature21029
sulzer2017:
authors: Sulzer D, et al.
title: T cells from patients with Parkinson's disease recognize α-synuclein peptides PMID: 41775328
journal: Nature
year: 2017
doi: 10.1038/nature22815
gray2013:
authors: Gray MT, Woulfe JM
title: Striatal blood-brain barrier permeability in Parkinson's disease
journal: Acta Neuropathol Commun
year: 2013
doi: 10.1186/2051-5960-1-35
pmid: 24163339
sampson2016:
authors: Sampson TR, et al.
title: Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
journal: Cell
year: 2016
doi: 10.1016/j.cell.2016.11.018
hirsch2009:
authors: Hirsch EC, Hunot S
title: 'Neuroinflammation in Parkinson''s disease: a target for neuroprotection?'
journal: Lancet Neurology
year: 2009
doi: 10.1016/S1474-4422(09)70130-4
pmid: 19592382
depboylu2012:
authors: Depboylu C, et al.
title: Deficient monocyte activation in Parkinson's disease
journal: PLoS ONE
year: 2012
doi: 10.1371/journal.pone.0011431
lawson1990:
authors: Lawson LJ, et al.
title: Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain
journal: Neuroscience
year: 1990
doi: 10.1016/0304-3940(90)90128-C
pmid: 1978681

Neuroinflammation in Parkinson's Disease

Overview

Neuroinflammation in [Parkinson's Disease](/diseases/parkinsons-disease) describes a key molecular or cellular mechanism implicated in neurodegenerative disease, including [Alzheimer's disease](/diseases/alzheimers), [dementia with lewy bodies](/diseases/dementia-with-lewy-bodies), and [multiple system atrophy](/diseases/multiple-system-atrophy). This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.

Chronic neuroinflammation is now recognized as a central pathogenic mechanism in [Parkinson's disease](/diseases/parkinsons-disease) (PD), contributing to [dopaminergic neuron](/cell-types/dopaminergic-neurons) degeneration in the [substantia nigra](/brain-regions/substantia-nigra) through multiple interconnected pathways involving [microglial](/cell-types/microglia) activation, [alpha-synuclein](/proteins/alpha-synuclein) aggregation, and [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction). Unlike acute inflammation that resolves with healing, neuroinflammation in PD becomes self-perpetuating through feed-forward loops involving microglial activation, peripheral immune infiltration, and the innate immune response to misfolded α-synuclein. This page provides a comprehensive mechanistic overview of neuroinflammatory pathways in PD and their therapeutic implications.

Microglial Biology in PD

Microglial Phenotypes

Microglia exist on a spectrum of activation states rather than binary M1/M2 polarization[@heneka2018]:

Pro-inflammatory (Classical M1-like) Features:

• Morphology: Amoeboid, retracted processes
• Markers: CD68, CD86, MHC-II, iNOS
• Cytokines: TNF-α, IL-1β, IL-6, IL-12, IL-23
• Effector molecules: ROS (superoxide, H₂O₂), RNS (NO, peroxynitrite)
• Receptors: TLR2, TLR4, RAGE, P2X7

• Morphology: Ramified, extended processes
• Markers: CD206, Arg1, Ym1, TGF-β
• Cytokines: IL-10, TGF-β
• Functions: Phagocytosis, debris clearance, trophic support
• Growth factors: BDNF, GDNF, IGF-1

• Chronic shift toward M1 phenotype
• Impaired M2 transition (failed resolution)
• Reduced phagocytic capacity despite activation
• Tonic (sustained) rather than phasic activation

Microglial Priming and Aging

With aging, microglia become "primed" — more reactive to stimuli with impaired resolution[@streit2012]:

• Fractalkine signaling decline: Reduced CX3CR1 (microglial) / CX3CL1 (neuronal) anti-inflammatory signaling
• DAM (disease-associated microglia) phenotype: Upregulation of APOE, TREM2, CST7; downregulation of homeostatic genes (P2RY12, TMEM119)
• Senescent microglia: SASP (senescence-associated secretory phenotype) with chronic cytokine production
• Iron accumulation: Increased ferritin, labile iron pool → oxidative stress

α-Synuclein as a Microglial Activator

Extracellular α-synuclein activates microglia through multiple receptors[@kim2015]:

| Receptor | α-Syn Form | Downstream Signaling | Consequence |
|----------|------------|---------------------|-------------|
| TLR2 | Fibrils, oligomers | MyD88 → NF-κB | TNF-α, IL-1β production |
| TLR4/MD2 | Aggregates | MyD88/TRIF → NF-κB, IRF3 | Pro-inflammatory cytokines |
| P2X7 | Aggregates | K⁺ efflux → NLRP3 | Inflammasome activation |
| RAGE | Oligomers | MAPK, NF-κB | Chronic inflammation |
| FcγR | Antibody-bound | ITAM → Syk | Phagocytosis, ROS |
| LAG3 | Fibrils | Endocytosis | Cell-to-cell spread |
| Integrin αMβ2 | Fibrils | Phagocytosis | Internalization |

Impaired α-Synuclein Clearance

Microglial phagocytosis of α-synuclein becomes impaired in PD[@george2013]:

The NLRP3 Inflammasome in PD

The NLRP3 inflammasome is a cytosolic multiprotein complex that activates caspase-1, leading to IL-1β and IL-18 maturation[@gordon2018]:

Evidence for NLRP3 in PD:

• Elevated NLRP3, ASC, caspase-1 in PD substantia nigra
• alpha-Synuclein fibrils activate NLRP3 in microglia
• NLRP3-deficient mice are protected in MPTP and alpha-Syn models
• MCC950 (NLRP3 inhibitor) is neuroprotective in preclinical PD

Astrocyte Contributions

Reactive Astrogliosis in PD

Astrocytes respond to PD pathology with both protective and harmful effects[@liddelow2017]:

A1 Neurotoxic Astrocytes:

• Induced by microglial IL-1α, TNF-α, C1q
• Markers: C3, Serping1, Amigo2
• Lose neurotrophic functions (reduced GDNF, BDNF)
• Gain neurotoxic properties (complement, ROS)
• Abundant in PD substantia nigra

• Induced by ischemia, trauma
• Markers: S100A10, PTX3, Emp1
• Upregulate neurotrophic factors
• Promote tissue repair

• Reduced glutamate uptake (GLT-1/EAAT2 downregulation)
• Impaired metabolic support to neurons
• α-Synuclein accumulation in astrocytes
• Gap junction dysfunction (Cx43)

Peripheral Immune Involvement

T Cell Infiltration

CD4⁺ and CD8⁺ T cells infiltrate the substantia nigra in PD[@sulzer2017]:

| T Cell Subset | Role in PD | Evidence |
|---------------|------------|----------|
| CD4⁺ Th1 | Pro-inflammatory, IFN-γ | Elevated in PD CSF |
| CD4⁺ Th17 | Neurotoxic, IL-17 | Correlates with severity |
| CD4⁺ Treg | Neuroprotective, IL-10 | Reduced in PD |
| CD8⁺ Cytotoxic | Direct neuronal killing | Found near dying neurons |
| γδ T cells | Innate-like, IL-17 | Elevated in PD blood |

α-Synuclein-Specific T Cells:

• T cells recognizing α-syn epitopes (30-50% of PD patients)
• Clonal expansion of specific TCR sequences
• May precede motor symptoms (prodromal marker)

Blood-Brain Barrier Dysfunction

BBB integrity is compromised in PD[@gray2051]:

• Tight junction loss: Claudin-5, occludin, ZO-1 downregulation
• Vascular inflammation: VCAM-1, ICAM-1 upregulation
• Pericyte dysfunction: Reduced coverage, PDGF-BB signaling
• MMP activation: MMP-2/9 degrade basement membrane
• Cerebral endothelial activation: NF-κB, AP-1 signaling

Gut-Brain Axis

The gut-brain axis contributes to peripheral inflammation in PD[@sampson2016]:

• Gut dysbiosis: Altered microbiome composition, reduced SCFA-producing bacteria
• Intestinal permeability: Leaky gut → LPS translocation
• Enteric glia activation: α-Syn accumulation in ENS
• Vagal pathway: Ascending α-Syn propagation
• Peripheral LPS: Activates systemic and central inflammation

Molecular Mediators

Cytokines and Chemokines

| Mediator | Cellular Source | Target Effect | PD Evidence |
|----------|-----------------|---------------|-------------|
| TNF-α | Microglia, astrocytes | Neuronal death, NF-κB activation | Elevated in SN, CSF |
| IL-1β | Microglia (inflammasome) | Fever, endothelial activation, neurotoxicity | Correlates with progression |
| IL-6 | Microglia, astrocytes | Acute phase response, T cell differentiation | Elevated in serum |
| IFN-γ | Th1 cells, NK cells | MHC-II upregulation, microglial activation | Increased in PD |
| IL-10 | Tregs, M2 microglia | Anti-inflammatory, tissue repair | Reduced in PD |
| CCL2/MCP-1 | Microglia, astrocytes | Monocyte recruitment | Elevated in CSF |
| CXCL10/IP-10 | Microglia, endothelial | T cell recruitment | Increased in PD |

Reactive Oxygen and Nitrogen Species

Microglial ROS/RNS production directly damages neurons[@hirsch2009]:

• Superoxide (O₂•⁻): NOX2 activation, mitochondrial
• Hydrogen peroxide (H₂O₂): Dismutated from superoxide
• Hydroxyl radical (•OH): Fenton chemistry with iron
• Nitric oxide (NO): iNOS induction; inhibits Complex IV
• Peroxynitrite (ONOO⁻): NO + O₂•⁻; nitrates proteins

Complement System

Classical and alternative complement pathways are activated in PD[@depboylu2012]:

• C1q: Binds α-synuclein, marks synapses for removal
• C3: Opsonizes α-syn, promotes phagocytosis
• C5a: Activates microglia via C5aR1
• MAC (C5b-9): May form on neurons, sublethal damage
• Synaptic pruning: Excessive complement-mediated synapse elimination

Cell-Type Specific Vulnerability

The substantia nigra pars compacta (SNpc) is uniquely vulnerable to neuroinflammation[@lawson1990]:

| Vulnerability Factor | Mechanism |
|----------------------|-----------|
| High microglial density | 2x higher than other brain regions |
| Low calbindin | Reduced calcium buffering |
| Dopamine oxidation | Generates ROS, quinones |
| Iron accumulation | Catalyzes Fenton chemistry |
| Neuromelanin | Iron-binding, activates microglia |
| Complex I deficiency | Mitochondrial ROS, DAMPs |
| α-Synuclein burden | Chronic microglial activation |

Therapeutic Targets and Strategies

Anti-inflammatory Approaches

| Target | Agent | Mechanism | Status |
|--------|-------|-----------|--------|
| TLR2 | CU-CPT22, C29 | Antagonize TLR2/TLR6 | Preclinical |
| NLRP3 | MCC950, Dapansutrile | Inflammasome inhibition | Preclinical |
| TNF-α | Etanercept, Infliximab, XPro1595 | TNF neutralization | Phase II (XPro1595) |
| IL-1β | Canakinumab, Anakinra | IL-1β receptor blockade | Preclinical |
| P2X7 | JNJ-54175446 | Antagonist | Phase II (safety) |
| CSF1R | PLX3397, BLZ945 | Microglial depletion | Preclinical (concerns) |
| TREM2 | Antibodies | Agonist, enhance phagocytosis | Preclinical |
| Sphingosine-1-P | Fingolimod | S1P modulator, T cell sequestration | Phase II |

Microglial Modulation

Shifting M1 → M2:

• Minocycline: Inhibits microglial activation (mixed results in trials)
• Ibuprofen: NSAID with microglial effects (epidemiological protection)
• PPARγ agonists (pioglitazone): Promote M2 phenotype (Phase II negative)

• TREM2 agonist antibodies
• Anti-α-synuclein immunotherapy (passive/active vaccines)

Targeting Peripheral Inflammation

• Gut microbiome: Probiotics, prebiotics, FMT
• Vagal stimulation: Reduces peripheral and central inflammation
• Exercise: Anti-inflammatory effects, increased BDNF

Biomarkers of Neuroinflammation in PD

| Biomarker | Sample | Clinical Utility |
|-----------|--------|------------------|
| IL-6 | CSF, serum | Disease progression |
| TNF-α | CSF, serum | Severity correlation |
| YKL-40 (CHI3L1) | CSF | Microglial activation |
| sTREM2 | CSF | Microglial activity |
| CCL2/MCP-1 | CSF | Monocyte recruitment |
| Neurofilament light | Serum | Axonal damage |
| TSPO PET | Imaging | Microglial activation in vivo |

See Also

• [Alpha-Synuclein Aggregation](/proteins/alpha-synuclein)
• [Microglia](/cell-types/microglia)
• [Oxidative Stress — ROS production](/mechanisms/oxidative-stress)
• [Mitochondrial Dysfunction — DAMP source](/entities/mitochondria)
• [Gut-Brain Axis in Tauopathy](/proteins/tau)

External Links

• Allen Human Brain Atlas: [Neuroinflammation in PD gene expression](https://human.brain-map.org/microarray/search/show?search_term=neuroinflammation+parkinson) — Search for PD-related inflammation genes across brain regions
• Allen Cell Type Atlas: [Cell type-specific RNA-seq](https://brain-map.org/atlases-and-data/rnaseq) — View microglial gene expression in Parkinson's disease
• BrainSpan: [Developmental transcriptome](https://www.brainspan.org/rnaseq/search/index.html?search_term=microglia) — Microglial gene expression across brain development
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: BCL2L1
• [Microglial Efferocytosis Enhancement via GPR32 Superagonists](/hypothesis/h-470ff83e) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: CMKLR1
• [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style="color:#81c784;font-weight:600">0.60</span> · Target: ALOX12
• [Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy](/hypothesis/h-ac55ff26) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: ALOX15
• [Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution](/hypothesis/h-f71a9791) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: GPR37
• [Mitochondrial SPM Synthesis Platform Engineering](/hypothesis/h-13bbfdc5) — <span style="color:#ffd54f;font-weight:600">0.47</span> · Target: ALOX5

Related Analyses:

• [Immune atlas neuroinflammation analysis in neurodegeneration](/analysis/SDA-2026-04-02-gap-immune-atlas-neuroinflam-20260402) &#x1f504;
• [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Neuroinflammation in PD discovered through SciDEX knowledge graph analysis:

References